Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas

Journal of Neuro-Oncology

Volumn 68, Issue 2, 2004, Pages 113-121

  Ranuncolo, Stella M ^a   Varela, Mirta ^b   Morandi, Ana ^b   Lastiri, José ^b   Christiansen, Silvia ^b   Bal de Kier Joffé, Elisa ^a   Pallotta, María G ^b   Puricelli, Lydia Inés ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Astrocytoma; Glioma; Invasion; Mdm2; p16; p53; Tumor marker

Indexed keywords

PROTEIN MDM2; PROTEIN P16; PROTEIN P53; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN P16INK4A; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURVIVAL; CHEMICAL LABELING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; ADOLESCENT; BIOPSY; BRAIN TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; TIME;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; BIOPSY; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3242881204     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000027741.19213.99     Document Type: Article

References (39)

1. Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumours of the Nervous System. International Agency for Research on Cancer (IARC), Lyon, 2000
2. Zhu Y, Parada LF: The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2(8): 616-626, 2002
3. Ware ML, Berger MS, Binder DK: Molecular biology of glioma tumorigenesis. Hist Histopathol 18(1): 207-216, 2003
4. Besson A, Yong VW: Mitogenic signaling and the relationship to cell cycle regulation in astrocytoma. J Neuro-Oncol 51(3): 245-264, 2001
5. Chakravarti AB, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, Dyson NJ: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7(8): 2387-2395, 2001
6. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22(17): 3551-3555, 1994
7. Meltzer PS: MDM-2 and p53: a question of balance. J Natl Cancer Inst 86(17): 1265-1266, 1994
8. Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984-2991, 1998
9. Lu W, Lin J, Chen J: Expression of p14ARF overcomes tumor resistance to p53. Cancer Res 62(5): 1305-1310, 2002
10. Kondo S, Kondo Y, Hara H, Kaakaji R, Peterson JW, Morimura T, Takeuchi J, Barnett GH: Mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer 74(8): 1263-1268, 1996
11. Shapiro G, Edwards CD, Rollins BJ: The physiology of p16 (INK4A)-mediated G1 proliferative arrest. Cell Biochem Biophys 33(2): 189-197, 2000
12. Bortolotto S, Chiadó-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D: CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88(4): 554-557, 2000
13. Xiao ZX, Chen J, Levine AJ, Madjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375(6533): 694-698, 1995
14. Vousden KH: p53: death star. Cell 103(5): 691-694, 2000
15. Finlay CA, Hinds PW, Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57(7): 1083-1093, 1989
16. Louis DN, Gusella JF: A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11 (10): 412-415, 1995
17. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3(1): 19-26, 1993
18. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6(3): 217-223, 1996
19. Calogero A, Arcella A, De Gregorio G, Porcellini A, Mercola D, Liu C, Lombari V, Zani M, Giannini G, Gagliardi F, Caruso R, Gulino A, Frati L, Ragona G: The early growth response. gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res 7(9): 2788-2796, 2001
20. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19(33): 3816-3822, 2000
21. Rainov NG, Dobberstein KU, Balm H, Holzhausen HW, Lautenschläger C, Heidecke V, Burkett W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35(1): 13-28, 1997
22. Ng HK, Lo SY, Huang DP, Poon WS: Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 26(1): 1-5, 1994
23. Barbareschi M, Iuzzolino P, Pennella A, Allegranza A, Arrigoni G, Dalla Palma P, Doglioni C: p53 protein expression in central nervous system neoplasms. J Clin Pathol 45(7): 583-586, 1992
24. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: Mdm2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 75 (9): 1269-1278, 1997
25. Shiraishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, Kuratsu J, Ushio Y: Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 95(2): 249-257, 2002
26. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastoma. J Neuropathol Exp Neurol 56(2): 180-185, 1997
27. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M: Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neuro-Oncol 49(3): 197-203, 2000
28. Smith JS, Jenkins RB: Genetic alterations in adult diffuse glioma: occurrence, significance and prognostic implications. Front Biosci 5: D213-231, 2000
29. Schroeder R, Feisel KD, Ernestus RI: Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas. J Neuro-Oncol 56(2): 127-132, 2002
30. Phuphanich S, Ferrall S, Greenberg H: Long-term survival in malignant glioma. Prognostic factors. J Fla Med Assoc 80(3): 181-184, 1993
31. Sant M, van der Sanden G, Capocaccia R: Survival rates for primary malignant brain tumours in Europe. Eur J Cancer 34(14): 2241-2247, 1998
32. Korshunov A, Golanov A, Sycheva R: Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neuro-Oncol 58(3): 217-236, 2002
33. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paakko P, Vahakangas K: p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS 102(10): 786-792, 1994
34. Danks RA, Chopra G, Gonzales M, Orian JM, Kaye AH: Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery 37(2): 246-254, 1995
35. Al-Sarraj S, Bridges LR: Immunoreactivity in astrocytoma and its relationship to survival. Br J Neurosurg 9(2): 143-149, 1995
36. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Nakamura H, Kochi M, Kuratsu J, Sava H, Ushio Y: Analysis of homozygous deletion of the p16 gene and correlation with survival inpatients with glioblastoma multiforme. J Neurosurg 96(5): 815-822, 2002
37. Kirla R, Salminen E, Huhtala S, Nuutinen J, Talve L, Haapasalo H, Kalim H: Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki67 labeling in high grade astrocytomas treated with radiotherapy. J Neuro-Oncol 46(1): 71-80, 2000
38. Shono T, Tofilon P, Schaefer T, Parikh D, Liu T, Lang F: Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 62(4): 1069-1076, 2002
39. Wang TJ, Huang MS, Hong CY, Tse V, Silverberg G, Hsiao M: Comparisons of tumor suppressor p53, p21 and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Biochem Biophys Res Commun 287(1): 173-180, 2001